Evaluation of Immunogenicity and Cross-Protective Efficacy of a CpG-Adjuvanted Trivalent Inactivated Influenza Vaccine in Ferrets
Vaccines · 14.07.2026 · 14 (7) · 615
DOI: 10.3390/vaccines14070615 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 14.07.2026. Verfasst von Yanping Qiu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Huan Ke (Hebei) Biotechnology Co., Ltd., Shijiazhuang 050000, China. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Drug Research and Development National Science and Technology Major Project.
Abstract (Originalsprache)
Background/Objectives: Pandemic influenza remains a persistent global threat, and while vaccination is the primary preventive measure, conventional vaccines often induce narrow, strain-specific immunity. This study evaluated the immunogenicity, protective efficacy, and cross-protective potential of a CpG-adjuvanted trivalent inactivated influenza vaccine (CpG-TIV) administered intramuscularly at high and low doses in ferrets.
Methods
Groups of influenza-seronegative ferrets received two intramuscular injections, 3 weeks apart, of high- or low-dose CpG-TIV or a commercial non-adjuvanted trivalent vaccine. Three weeks after the second immunization (Day 42), serum was obtained, and the ferrets were subsequently challenged intranasally with homologous H1N1 and influenza B viruses, as well as a heterologous drifted H3N2 strain. Clinical signs, body weight, nasal viral load, and lung histopathology were monitored following the viral challenge.
Results
CpG-TIV induced significantly higher dose-dependent HI and IgG antibodies than the commercial unadjuvanted vaccine. High-dose CpG-TIV markedly reduced weight loss, clinical symptoms, nasal viral load (by up to 99%), and lung pathological damage. Notably, high-dose CpG-TIV provided significant cross-protection against heterologous H3N2, whereas the commercial vaccine showed no protective effect. At Day 42, HI GMTs in the high-dose group reached 500, 254, and 594 against H1N1, H3N2, and B strains, respectively, with a maximal 2.58 log10 reduction in H1N1 viral load.
Conclusions
High-dose CpG-TIV demonstrates strong immunogenicity and robust dose-dependent homologous and heterologous cross-protection in ferrets. The combination of a CpG adjuvant and high-dose antigen broadens protection against drifted influenza viruses, overcoming the narrow coverage of conventional vaccines. These data support further clinical development of this broad-spectrum influenza vaccine candidate.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Huan Ke (Hebei) Biotechnology Co., Ltd., Shijiazhuang 050000, China.
- Huapu Shijiazhuang Pharmaceutical Co., Ltd., Shijiazhuang 050000, China.
- Jiangsu KMQ BioTech Inc., Nantong 226000, China.
Förderung
- Innovative Drug Research and Development National Science and Technology Major Project
Zitieren
APA
Qiu, Y., Zhang, Y., He, S., Wang, Y., Wang, R., Han, Y., He, W., Sho, E., Han, S., & Wu, H. (2026). Evaluation of Immunogenicity and Cross-Protective Efficacy of a CpG-Adjuvanted Trivalent Inactivated Influenza Vaccine in Ferrets. Vaccines, 14(7), 615. https://doi.org/10.3390/vaccines14070615
Vancouver
Qiu Y, Zhang Y, He S, Wang Y, Wang R, Han Y, et al. Evaluation of Immunogenicity and Cross-Protective Efficacy of a CpG-Adjuvanted Trivalent Inactivated Influenza Vaccine in Ferrets. Vaccines. 2026;14(7):615. doi:10.3390/vaccines14070615
BibTeX
@article{Qiu2026,
author = {Qiu, Yanping and Zhang, Yan and He, Shuangshuang and Wang, Yutian and Wang, Ruixin and Han, Yanxiao and He, Wen and Sho, Eiketus and Han, Shaohua and Wu, Haojie},
title = {Evaluation of Immunogenicity and Cross-Protective Efficacy of a CpG-Adjuvanted Trivalent Inactivated Influenza Vaccine in Ferrets},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {7},
pages = {615},
doi = {10.3390/vaccines14070615}
}
EUVIMED